Our Pipeline
C. diff Treatment, NTM/TB, Gram-Positives & More
Crestone is a clinical stage company focused on developing small molecule drugs for serious bacterial infections. The R&D pipeline includes several programs that address areas of significant and growing unmet medical need, all with novel mechanism of action agents.
Program
CRS3123 for C. difficile
Program
CRS0540 Gram-positives
Program
CRS0393 NTM/TB
Pipeline Progress
CRS3123 for C. difficile
C. diff Treatment
CRS3123 is a small molecule protein synthesis inhibitor we’re developing and testing to treat C. diff Infection (CDI), a gastrointestinal condition caused by toxin-producing strains of C. difficile bacteria. Learn more about this promising treatment using the link below.
CRS0540 Gram-positives
We are developing a novel class of small molecule antibiotics targeting PolC, the replicative DNA polymerase in Gram-positive bacteria. By inhibiting a novel bacterial target, these compounds circumvent existing mechanisms of antibiotic resistance.
CRS0393 NTM/TB
We are developing a novel class of anti-mycobacterial agents (benzothiazole amides) that target the MmpL3 protein essential for cell wall synthesis. In collaboration with scientists at Colorado State University, the hit-to-lead program has resulted in advanced compounds that show excellent potency against all mycobacteria tested, including multidrug-resistant strains.
Become a Part of These Projects
Interested in helping further our research into novel antibacterial agents? We’d be thrilled to have your help, either as an investor or a team member.
Inquiries
Have a question or comment? Follow the link below to contact us about general inquiries.
Careers
Find work in a team-oriented environment at one of the leading Colorado pharma companies.
Investors
If you're interested in becoming an investor to help fund our research and development, contact us today.